Skip to main content
Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification

Fig. 1

KW-2478 inhibited the growth of BCR/ABL-positive cells with no obvious effect on BCR/ABL-negative cells. a The effects of KW-2478 on the growth of K562 and K562/G01 cells were assessed by CCK-8 assay after incubation for 24, 48 and 72 h. b The survival rate of PBMCs from two healthy individuals was detected by CCK-8 assay after incubation with KW-2478 for 48 h. c The IC50 values of KG-1a, THP1, KCL-22, K562, K562/G01, SUP-B15, 32DP-T315I and 32DP cells were detected by CCK-8 assay after 48 h of treatment with KW-2478. d, e The proliferation of CML cells after KW-2478 treatment was detected using a colony formation assay, and the results were statistically analysed. The scale bar represents 100 μm. The values are the mean standard deviation of three independent experiments. Asterisks denote statistically significant differences compared with the control group

Back to article page